Chinanews.com on April 27th, can the anti-tumor drugs enter the hospital after entering the medical insurance?

What is the current clinical use of these drugs?

On the 27th, He Jie, academician of the Chinese Academy of Sciences and director of the National Cancer Center, responded. The data shows that the average number of anti-tumor drugs in hospitals monitored by the surveillance network in 2020 has increased by 15% over the previous year, and the average number of inpatients using these drugs An increase of 6%, while the average cost has dropped by 8%, and the average cost of some more expensive immunotherapy drugs and targeted therapy drugs has decreased by 50%-70%.

  The National Health Commission held a press conference on the 27th. A reporter asked: At present, many anti-tumor drugs, especially new drugs, have been launched one after another. The state has also conducted some medical insurance negotiations. The people are more concerned about whether anti-tumor drugs can enter medical insurance. be hospitalized?

What is the current clinical use of these drugs?

  He Jie said that the Party Central Committee and the State Council attach great importance to the protection of anti-cancer drugs, especially since the 19th National Congress of the Communist Party of China, the price of anti-cancer drugs has been drastically reduced through national medical insurance negotiations and other means to increase the availability of anti-cancer drugs.

The National Health Commission attaches great importance to this work. On the one hand, it requires all medical institutions to allocate these drugs in a timely manner, and on the other hand, it requires all medical institutions to use anti-tumor drugs rationally.

  According to Hejie, starting in 2018, under the direct leadership of the National Health Commission, the National Cancer Center has established an anti-cancer drug clinical application monitoring network. This is the monitoring of anti-cancer drugs in more than 1,400 large hospitals across the country. The monitoring has promoted anti-cancer drugs. Standard and rational use of tumor drugs.

The data shows that in 2020, the average number of anti-tumor drugs in hospitals monitored by the Surveillance Network has increased by 15% over the previous year. The average number of inpatients using these drugs has increased by 6%, while the average cost has dropped by 8%. , The cost of some more expensive immunotherapy drugs and targeted therapy drugs has dropped by 50%-70%.

This shows that the availability of anti-tumor drugs has been significantly improved.

  "In addition, by monitoring the reasonable diagnosis and treatment behavior of tumors and the rational use of anti-tumor drugs, the entire medical behavior specification is strengthened. For example, in 2020, we conducted statistics on the monitored hospitals and found that the pathological examination of patients using anti-tumor drugs The gold standard has increased by 6% compared with the previous year, which means it is more standardized." Hejie added.

  Hejie also pointed out that in hospitals of different levels and categories, there are still differences in the configuration of anti-tumor drugs and the level of drug use, because the level of hospitals is different, and the level of doctors is different, so there will definitely be some differences.

"We are gradually improving through homogeneity, just like the quality control just mentioned, and gradually make up for the weaknesses in this area."

  Hejie said that in the future, the National Cancer Center will continue to monitor the clinical application of anti-tumor drugs, analyze, evaluate and improve the use of key drugs, and better guide the clinical rational deployment and use of anti-tumor drugs, and contribute to the national health. The Health Commission provides a reference basis for the assessment of various medical institutions.